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Abstract
Background: The death toll associated with inhaled ambient particulate matter (PM) is attributed mainly to cardio-
vascular rather than pulmonary effects. However, it is unclear whether the key event for cardiovascular impairment
is particle translocation from lung to circulation (direct effect) or indirect effects due to pulmonary particle-cell
interactions. In this work, we addressed this issue by exposing healthy mice via inhalation and intra-arterial infusion
(IAI) to carbon nanoparticles (CNP) as surrogate for soot, a major constituent of (ultrafine) urban PM.
Methods: Equivalent surface area CNP doses in the blood (30mm2 per animal) were applied by IAI or inhalation
(lung-deposited dose 10,000mm2; accounting for 0.3% of lung-to-blood CNP translocation). Mice were analyzed for
changes in hematology and molecular markers of endothelial/epithelial dysfunction, pro-inflammatory reactions,
oxidative stress, and coagulation in lungs and extra-pulmonary organs after CNP inhalation (4 h and 24 h) and CNP
infusion (4 h). For methodological reasons, we used two different CNP types (spark-discharge and Printex90), with
very similar physicochemical properties [≥98 and ≥95% elemental carbon; 10 and 14 nm primary particle diameter;
and 800 and 300 m2/g specific surface area] for inhalation and IAI respectively.
Results: Mild pulmonary inflammatory responses and significant systemic effects were observed following 4 h and
24 h CNP inhalation. Increased retention of activated leukocytes, secondary thrombocytosis, and pro-inflammatory
responses in secondary organs were detected following 4 h and 24 h of CNP inhalation only. Interestingly, among
the investigated extra-pulmonary tissues (i.e. aorta, heart, and liver); aorta revealed as the most susceptible
extra-pulmonary target following inhalation exposure. Bypassing the lungs by IAI however did not induce any
extra-pulmonary effects at 4 h as compared to inhalation.
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Conclusions: Our findings indicate that extra-pulmonary effects due to CNP inhalation are dominated by indirect
effects (particle-cell interactions in the lung) rather than direct effects (translocated CNPs) within the first hours after
exposure. Hence, CNP translocation may not be the key event inducing early cardiovascular impairment following air
pollution episodes. The considerable response detected in the aorta after CNP inhalation warrants more emphasis on
this tissue in future studies.
Keywords: Inhaled soot, Ultrafine particulate matter, Inflammation, Lung, Heart, Aorta, Cardiovascular, Particle
translocation
Background
Epidemiological studies have linked both short-term and
long-term particulate matter (PM) exposures to in-
creased morbidity and mortality [1–4]. The World
Health Organization (WHO) estimated over 800,000
premature deaths worldwide per year to be attributed to
PM air pollution [5]. Cardiovascular impairments have
been identified by several epidemiological studies as a
major PM associated health risk accounting for more
fatalities than pulmonary effects [6–10]. Ultrafine or
nano-sized carbon particles (UfCP; diameter less than
100 nm) originating from incomplete combustion pro-
cesses (soot) have been hypothesized as the major PM
constituent contributing of cardiovascular effects [11]
(mainly because of their: 1) greater pulmonary depos-
ition and retention efficiency in the lung periphery
compared to larger sized particles [12, 13]; 2) enhanced
oxidant capacity [14, 15]; 3) higher pulmonary pro-
inflammatory potential [16, 17]; and 4) higher effi-
ciency to penetrate the epithelium to reach interstitial
sites or even translocate to the systemic circulation
and secondary organs (such as brain, heart, aorta, liver
etc.) [18–24].
Exposure to urban UfCPs has increased dramatically
over the last decades primarily due to the techno-
logical revolution resulting in increased emissions of
combustion-derived ultrafine particles (soot) from traf-
fic, industry, and heating activities [17]. Consequently,
the major constituent of urban ultrafine particles is
soot, i.e. carbonaceous material consisting of an elem-
ental carbon core surrounded by various types of or-
ganic carbon and small fractions of metal, sulfate, and
nitrate compounds [25, 26]. Elemental carbon nano-
particles (CNPs; primary particle diameter ~ 25 nm)
constitute the core of combustion derived particles
[27] and represent a relevant toxicological surrogate
for exhaust particles from diesel engines, if particle
surface area is used as dose metric [28, 29]. Motor-
vehicle emissions consist of a complex mixture of par-
ticulate, chemical and gaseous pollutants such as fine
particulate matter (PM2.5; diameter < 2.5 μm), ultra-
fine particles (UFPs; diameter < 0.1 μm), metals, vola-
tile organic material, black carbon, ozone etc. [30]. A
major component of urban PM air pollution is CNPs.
They constitute the core of combustion derived parti-
cles [27] and represents relevant surrogates for exhaust
particles from modern diesel engines [28, 29]. In-
creased use of engineered nanoparticles has made CNP
as an evolving source of human exposure [17]. How-
ever, it is to be considered that engineered CNPs and
ambient UfCPs in spite of their similar sizes (<100 nm)
are likely to have different modes of action, but may
also share certain common modes of action, particu-
larly those driven by the elemental carbon core.
Plausible mechanisms of UfCP-mediated cardiovascu-
lar effects have been addressed in many studies. We have
previously shown that exposing young and healthy mice
to high number concentrations of CNPs induces local
acute inflammatory effects in the lung [31]. Further-
more, we could reproduce the epidemiological findings
of PM-related cardiovascular risks in an experimental
setting by exposing spontaneously hypertensive rats
(SHRs) with ambient dust and CNPs [30, 32, 33]. We
detected not only blood pressure changes and heart rate
variability, but our findings also indicated promotion of
endothelial dysfunction and thrombogenesis as the
plausible causes for cardiovascular impairments trig-
gered by pulmonary CNP deposition [34, 35]. Others
have shown that CNP inhalation causes acute vascular
effects in healthy and asthmatic subjects, indicated by
changes in peripheral blood leukocyte distribution and
adhesion molecule expression [36, 37].
It is generally assumed that PM exposure elicits low-
grade systemic inflammation and subsequent changes in
vascular function, such as increased blood leukocyte and
platelet counts, and fibrinogen levels which in turn can
result in cardiovascular impairments [38]. Therefore,
endothelial dysfunction, inflammation, pro-inflammatory
cytokine imbalance, oxidative stress, and dysregulated
coagulation pathways may be considered as the trigger-
ing events of cardiovascular impairments due to particu-
late air pollution. Several hypotheses have been put
forward to explain the mechanisms through which in-
haled particles can interact with the cardiovascular sys-
tem [8, 39]. The classical concept is that inhaled
particles locally evoke an inflammatory response in the
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lung with subsequent releases of pro-inflammatory and/
or pro-thrombotic mediators into the circulation [11]. In
addition to this indirect effect on circulation and extra-
pulmonary organs, more recent studies suggest that
particularly inhaled insoluble nanoparticles (but not
micron-sized particles) are capable of rapid translocation
into the circulation [21, 40] thereby affecting hemostasis
and cardiovascular integrity by direct CNP interaction
with circulation and extra-pulmonary organs [41, 42]. In
this direct mode of action, the lungs act as an efficient
port of entry of the primary toxin (CNPs in this case),
while in the indirect mode of action the lungs act as me-
diator or even amplifier of a local (pulmonary) inflam-
matory response yielding systemic effects. The direct
mode of action is supported by the findings of Nurkiewicz
and colleagues [43] who reported systemic microvascular
responses in rats following pulmonary exposure to re-
sidual oil fly ash and TiO2 independent of the degree of
pulmonary inflammation. In another more direct ap-
proach, we have shown that a moderate dose of 107 intra-
arterially infused CNPs induced platelet accumulation in
the hepatic microvasculature of mice [34]. This was asso-
ciated with pro-thrombotic changes on the endothelial
surface of hepatic microvessels. Similarly, inhalation of
CNPs evoked platelet adhesion and fibrinogen deposition
in mice at corresponding doses [35]. However, the key
question that still remains to be answered; i.e. whether the
extra-pulmonary effects following inhalation of insoluble
particles result from molecular events initiated in the
lungs (indirect mode) or translocation of particles beyond
the lungs (direct mode) drives the extra-pulmonary ef-
fects, or both.
The overarching aim was to investigate, if extra-
pulmonary effects of CNP inhalation can be explained
by direct interactions of lung-blood translocated parti-
cles on extra-pulmonary tissue (i.e. heart, liver, aorta) or
if the local particle-lung cell interaction in lung is the
key event. To pursue this, we have compared pulmonary
and systemic effects for two routes of CNP application
at equivalent dose, namely CNP application directly into
the blood stream (intra-arterial infusion/IAI) and pul-
monary application (inhalation) with likely subsequent
translocation of a small CNP fraction into the blood
stream. BALB/cJ mice were assessed after 4 h and 24 h
inhalation exposure, or 4 h after IAI. Time points were
selected based on our previous studies showing that in
lungs, CNPs induced a two-phase inflammatory re-
sponse after 4 or 24 h inhalation [31], whereas the extra-
pulmonary pro-coagulatory impact in the hepatic micro-
vasculature was detected as early as 2 h after CNP IAI
application [34, 35]. Therefore, we sought to systematic-
ally and independently investigate the two potential
modes of action by applying (i) similar CNPs, as used in
several of our previous studies [44–48] and (ii) equivalent
doses of CNP in mice via inhalation or intra-arterial infu-
sion (IAI) and subsequent comparison of the effects in the
lung, blood, and secondary target organs such as heart,
aorta, and liver.
Results
Our analysis strategy involved different body compart-
ments namely, bronchoalveolar space, lung tissue, blood
(cells and plasma), heart, liver and aorta thereby provid-
ing a comprehensive assessment of each compartment
in terms of endothelial/epithelial activation, inflamma-
tion, and oxidative stress, on the protein and gene ex-
pression level. According to the current understanding
and as previously outlined by Kermanizadeh et al. [49],
oxidative stress, inflammation, cytotoxicity and dysfunc-
tion of cellular/physiological processes present the likely
causal mechanism of toxicological effects in secondary
organs following inhalation and eventually translocation
of nanoparticles. All data discussed here are compared
to the corresponding time-matched control and are sta-
tistically significant (p < 0.05). In case of transcript or
protein expression data, which was generated from
pooled tissue samples, we have only discussed molecules
with ≥2 fold increased or decreased expression levels
[Additional file 1: Table S1].
To sum up the events matching to experimental
design timings: The pro-inflammatory response was de-
tectable at the protein level already after the first 4 h of
CNP inhalation exposure. It is plausible that the pro-
inflammatory mediators are released from, i) intracellu-
lar stores (vesicles) [50]; or ii) extracellular stores (matrix
immobilized) [51]. However neutrophil recruitment to
the lungs and development of a pro-inflammatory gene
expression signature might take longer time. Thus, a
moderate but significant pro-inflammatory gene signa-
ture is detected after a 24 h CNP inhalation. Whereas in
case of IAI, pro-inflammatory protein and gene signa-
ture is completely absent at 4 h even if the applied IAI
dose is equivalent to the calculated translocated amount
within 24 h of inhalation. Therefore, we believe, by
avoiding the 24 h IAI time point we implemented the re-
duction of animal use principle of the “3R–tenet” with-
out significantly compromising scientific quality. Our
experimental strategy was also based on our previous ex-
perience where we observed that in case of IAI the time
point of 2 h was sufficient to develop platelet – endothe-
lial interactions [34]. Hence, we strategized to investigate
at 4 h after IAI of CNP allowing an additional 2 h for
further downstream effects. The 4 h time point investi-
gated in this study is also based on the fact that platelet
– endothelial interactions have also been detected
already 2 h after CNP inhalation and effects did not in-
crease 8 h thereafter [34].
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Pulmonary response
In line with previous results [30], CNP inhalation caused
a moderate, acute inflammatory response in the lungs.
Accordingly, BAL fluid analysis revealed a mild but sig-
nificant neutrophilic granulocyte influx resulting in
10.2 ± 2.5 × 103 neutrophils (versus 2.5 ± 0.8 × 103 in
controls) in the CNP exposed group after 24 h inhalation
[Fig. 1; Additional file 1: Table S2]. BAL protein concen-
tration was increased after 4 h CNP inhalation and
returned to basal levels after 24 h inhalation [Additional
file 1: Table S3]. The analysis of BAL cytokine levels re-
vealed an initially decreased concentration of CXCL1 (2.6
fold) after 4 h inhalation, while CXCL1 was increased 4.5
fold over control levels after 24 h CNP inhalation, which
is in agreement with elevated BAL neutrophil numbers.
Other more monocyte/macrophage, but not directly to
granulocyte recruitment related cytokines such as CCL2,
IL1a and IL12p40 showed non-elevated levels in the CNP
exposed animals [Additional file 1: Table S3] thereby sup-
porting the mild nature of the inflammation.
Transcript expression analysis of 59 genes representative
of endothelial/epithelial dysfunction, pro-inflammatory
reactions, oxidative stress, and coagulation in the lung tis-
sue was performed to characterize the response pattern
after inhalation or IAI of CNPs [Fig. 2a, Additional file 1:
Table S4]. As shown by the BAL data, CNP inhalation
caused a pro-inflammatory signature in lung tissue ex-
tracts with elevated levels of fibrinogen (Fga, −b, −g) and
cytokine (Il10, Cxcl1, −2, −5) transcript expression after
24 h CNP inhalation as well as high abundance of proteins
associated with inflammation and endothelial/epithelial
activation after 4 h and 24 h CNP inhalation (Fig. 2a, b).
In contrast to inhalation, 4 h after CNP IAI no pro-
inflammatory changes could be detected in the lungs, in-
dicating that this route of exposure effectively bypassed an
inflammatory stimulation of the lung tissue within the 4 h
time window of investigation. Hence, we conclude that
IAI application of CNPs resulted in direct extra-
pulmonary effects only, while inhalation of CNPs may
have resulted in both direct pulmonary and indirect extra-
pulmonary effects.
Blood response
Hematological analysis revealed increased granulocyte
(1.6-fold) and monocyte (1.8-fold) counts after 24 h
CNP inhalation exposure indicating a mild inflam-
matory, systemic reaction (Fig. 3a, b; Table 1; Additional
file 1: Table S5). Following IAI of CNP, only a mild in-
crease in lymphocyte counts (1.3-fold) was detected.
Total platelet count was slightly increased by 1.5-fold
after 4 h and 1.3-fold after 24 h of CNP inhalation (Fig.
3a, Table 1, Additional file 1: Table S5). Interestingly,
only post CNP inhalation the quantity of large platelets
was strongly affected showing a > 9-fold (at 4 h) and >2-
Fig. 1 Analysis of bronchoalveolar lavage (BAL) cell differentials
following carbon nanoparticle (CNP) inhalation exposure in
BALB/cJ mice compared to control. a. Total BAL cell counts do
not exhibit any significant changes. BAL cell analysis following
CNP inhalation exposed mice revealed increased macrophages
(b) [Control: 5.5 ± 0.8 × 105 versus 6.7 ± 0.8 × 105] at 4 h post
exposure followed by a strong granulocyte influx (c) [Control:
2.6 ± 0.8 × 103 versus 10.0 ± 2.8 × 103] at 24 h post exposure.
Data are shown as Mean ± SEM; n = 8 and asterisks (*) denote
p < 0.05. White bars: Clean air exposed; Black bars: CNP exposed
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fold (at 24 h) increase. This suggests that 4 h pulmonary
exposure to CNP initiated a reactive thrombocytosis
which persisted through 24 h of CNP inhalation.
Thrombocytosis is considered as a predisposing event to
atherosclerotic plaque formation. Recently, Tabor et al.
[52] reported accelerated arterial thrombus formation in
rat models following diesel exhaust particle exposure
due to increased platelet activation independent of pul-
monary and systemic inflammation or impaired fibrino-
lytic function. Increase of large platelets indicates the
formation of new platelets thereby increasing the total
platelet count. Large platelets are also associated with
(See figure on previous page.)
Fig. 2 Heatmap representation of lung transcript and protein panel assays following inhalation and intra-arterial infusion exposure of carbon nanoparticles
(CNP). a. Transcript expression levels of 59 genes representing epithelial/endothelial activation, inflammatory cell markers, inflammation mediators and
oxidative stress are shown. b. Protein expression levels of 34 markers representing epithelial/endothelial activation, inflammatory cell markers,
inflammation mediators are shown. Samples were pooled from 4 animals/experimental group for transcript and protein analysis. Expression
values are provided as percentage relative to time matched control. Fold changes below 1.5 were considered insignificant and are indicated
in black color. IHA: inhalation; IAI: intra-arterial infusion
Fig. 3 Hematological analysis of blood samples following inhalation and intra-arterial infusion of carbon nanoparticle (CNP) in mice compared
to control. CNP exposure related changes are shown as percentage relative to control. a. Granulocyte and monocyte numbers were increased
in the blood following 24 h CNP inhalation exposure. [Granulocytes: 0.46 ± 0.09 versus 0.75 ± 0.05 × 10E3; Monocytes: 0.04 ± 0.01 versus
0.07 ± 0.01 × 10E3 cells/ml blood]. Platelet counts, particularly that of large platelets, were significantly increased both after 4 h and 24 h post
exposure periods. [Platelet (4 h post exposure): 810 ± 87 versus 1203 ± 55; Platelet (24 h post exposure): 869 ± 97 versus 1104 ± 18 and Large
platelet (4 h post exposure): 1.9 ± 0.4 versus 17.6 ± 2.7; Large platelet (24 h post exposure): 4.3 ± 1.3 versus 9.0 ± 1.3 x10E3 cells/ml blood]. b.
Intra-arterial infusion of CNP resulted in increased lymphocyte counts after 4 h [Lymphocyte: 1.52 ± 0.07 versus 1.92 ± 0.13 x10E3 cells/ml
blood] but the platelet count remained unaltered. Data are shown as Mean ± SEM; inhalation: n = 8, infusion: n = 6 and asterisks (*)
denote p < 0.05. WBC: White blood cell; Neutro: neutrophilic granulocytes; Mono: Monocytes; Lympho: Lymphocytes; RBC: Red blood
cells; PLT: Platelets; Large PLT: Large platelets
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platelet activation during hemostasis. In accordance, also
other platelet indices characterizing platelet volume and
granularity (e.g. MPV, PTC, MPC, PCDW and MPM)
were altered both after 4 h and 24 h CNP inhalation
(Table 1). These findings all together support the notion
of platelet activation after CNP inhalation. In contrast,
platelet count, platelet shape, and platelet activity pa-
rameters remained unchanged following IAI (Fig. 3b,
Table 1, Additional file 1: Table S5). The recent pioneer-
ing work from Lefrançais et al. [53] demonstrated lung
as an important site of local platelet biogenesis and a po-
tent reservoir for haematopoietic progenitors. In light of
their findings [53], it is plausible that local, pulmonary
stress-response to particle inhalation may eventually via
local reactive oxygen species (ROS) formation [54] di-
rectly lead to rapid increases of blood platelet numbers
and thereby increase the risk for cardiac infarction with-
out involving further systemic cytokine elevations and
bone marrow activation.
In view of the observed changes in blood neutrophil
and monocyte numbers and following the human expos-
ure study from Frampton and colleagues [36], we add-
itionally investigated the surface expression of the
adhesion molecules CD11b, CD18 and CD49d to assess
the activation status of these circulating leukocytes.
Similar to the findings of Framton et al. [36] in human,
reduced surface expression of CD49d, CD11b (24 h) and
CD18 (4 h) was noted on granulocytes after CNP inhal-
ation (p < 0.05; n = 8). Also for monocytes a reduced
CD18 expression was observed after both time points
(Fig. 4 a, b). No effect, however, was observed following
IAI (Fig. 4 c, d). Reduced surface expression of β1 and
β2 integrin leukocyte adhesion molecules CD11b, CD18
and CD49d in peripheral blood monocytes and granulo-
cytes particularly 24 h post inhalation may indicate an
impeding effect on peripheral blood leukocyte distribu-
tion, arguing for an increased retention of activated cells
in the pulmonary vascular bed due to CNP inhalation.
In this context, an inflammatory activation of monocytes
and neutrophils in the vascular bed of CNP exposed
lungs, with increased expression of CD11b and CD18
integrins, is likely to decrease cell deformability via actin
polymerization, again contributing to leukocyte reten-
tion and reduced capillary flow [55]. As mentioned
before, very similar responses have previously been de-
scribed in CNP-exposed healthy and asthmatic subjects
[36]. In this study also a reduction in pulmonary diffus-
ing capacity for carbon monoxide in CNP exposed
individuals was observed, additionally supporting the hy-
pothesis of Frampton and colleagues, of a mismatch in
ventilation and pulmonary vascular perfusion and pul-
monary capillary flow caused by CNP inhalation.
A panel of 25 protein analytes known to be associated
with cardiovascular diseases consisting of acute phase reac-
tants, soluble inflammatory adhesion molecules, inflamma-
tion related proteinases, and cytokines were screened in
the plasma (Additional file 1: Table S6). Only the plasma
levels of the cytokines GM-CSF (2.3 fold) and IL1α (4.6
fold) were more than 2-fold reduced following CNP inhal-
ation after 4 and 24 h CNP exposure (p < 0.05; n = 8; Fig.
5a). No difference equaling or exceeding a 2-fold change
could be detected following IAI of CNPs (Fig. 5b). Note-
worthy, the concentrations of some cytokines and acute
phase reactants, i.e. fibrinogen, PAI-1, CXCL1, G-CSF, and
IL-6, but also CCL2 and CCL5 were markedly higher in
controls of the IAI groups compared to the inhalation sce-
nario, which may indicate an acute phase response caused
by the surgical procedure rather than CNP exposure and,
thus, may limit the interpretation of these specific end-
points. Yet other cytokines in particular IL-1a and - b,
Table 1 Hematological analysis of blood samples for platelet parameters following inhalation (4 h and 24 h) and intra-arterial infu-
sion (4 h) of carbon nanoparticle (CNP) in mice compared to control
Platelet Parameters Inhalation Intra-arterial Infusion
4 h 24 h 4 h
Control CNP p Control CNP p Control CNP p
PLT (×10E3 CELLS/μL) 809.50 ± 86.95 1203.13 ± 54.84 *↑ 868.50 ± 96.65 1103.57 ± 17.77 *↑ 902.50 ± 62.56 909.67 ± 69.40 NS
Large PLT (×10E3 CELLS/μL) 1.88 ± 0.40 17.63 ± 2.71 *↑ 4.25 ± 1.32 9.00 ± 1.34 *↑ 22.33 ± 4,72 25.50 ± 5.60 NS
MPV (fl) 5.45 ± 0.15 7.66 ± 0.16 *↑ 5.99 ± 0.29 7.04 ± 0.10 *↑ 7.97 ± 0.30 8.28 ± 0.58 NS
PCT (%) 0.45 ± 0.06 0.92 ± 0.04 *↑ 0.53 ± 0.08 0.78 ± 0.02 *↑ 0.73 ± 0.07 0.74 ± 0.06 NS
PDW (%) 51.65 ± 1.15 58.70 ± 0.79 *↑ 53.63 ± 2.37 56.99 ± 1.02 NS 68.83 ± 2.52 65.25 ± 1.70 NS
MPC (g/dl) 24.93 ± 0.42 19.86 ± 0.32 *↓ 23.53 ± 0.72 21.29 ± 0.21 *↓ 19.90 ± 0.58 19.58 ± 1.12 NS
PCDW (g/dl) 7.41 ± 0.17 8.10 ± 0.08 *↑ 7.61 ± 0.24 8.21 ± 0.06 *↑ 7.95 ± 0.10 7.93 ± 0.11 NS
MPM (pg) 1.23 ± 0.01 1.26 ± 0.01 *↑ 1.24 ± 0.01 1.27 ± 0.01 *↑ 1.31 ± 0.01 1.31 ± 0.01 NS
PMDW (pg) 0.43 ± 0.01 0.42 ± 0.01 NS 0.43 ± 0.01 0.43 ± 0.01 NS 0.49 ± 0.01 0.48 ± 0.01 NS
PLT platelet, Large PLT large platelet count, MPV mean platelet volume, PCT plateletcrit, PDW platelet distribution width, MPC mean platelet component, PCDW
Platelet component distribution width, MPM mean platelet mass, PMDW platelet mass distribution width. Data is shown as Mean ± SEM; inhalation: n = 8; infusion:
n = 6; * p < 0.05; ↑: significantly increased; ↓: significantly decreased; NS not significant
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known to show up early during an inflammatory response,
remain unchanged between inhalation and IAI controls.
Transcript and protein analysis in extra-pulmonary organs
Transcript and protein panel assays were carried out in
heart, aorta, and liver tissue (Fig. 6; Additional file 1:
Table S7) to assess and compare the effect of CNP ex-
posure via inhalation and IAI routes. After CNP inhal-
ation transcript analysis of the heart detected several
inflammatory cell markers, such as Lcn2, Lgals3, Ly6g,
Olr1 and Spp1 as well as the cytokines Cxcl1, Il1a and
Il6 to be elevated (Fig. 6). In contrast, only the
Fig. 4 Characterization of peripheral blood monocytes and leucocytes for surface expression of adhesion molecules following inhalation and
intra-arterial infusion of carbon nanoparticle (CNP) in mice compared to control using fluorescent automated cell sorting (FACS). a. Reduced
expression of CD49d and CD11b was noted in granulocytes after 24 h of CNP inhalation exposure whereas CD18 expression was reduced in
granulocytes at both 4 h and 24 h post inhalation exposure. b. Reduced expression of CD49d in monocytes was observed after 24 h of CNP
inhalation exposure, while reduced CD18 expression in monocytes was noted following both 4 h and 24 h post CNP inhalation exposure. c.
No altered expression of CD49d, CD11b and CD18 was noted in granulocytes following 4 h of intra-arterial infusion of CNP. d. No altered
expression of CD49d, CD11b and CD18 was noted in monocytes following 4 h of intra-arterial infusion of CNP. Data are shown as Mean ± SEM;
inhalation: n = 8, infusion: n = 6; and asterisks (*) denote p < 0.05. White bars: Clean air exposed; Gray bars: CNP exposed
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antioxidant response gene Gsta1 was more than 2-fold in-
duced by IAI. Similarly, liver extracts showed increased
levels for inflammation-related transcripts Fn1 and Il1a
after CNP inhalation exposure only. Aorta samples, in
fact, revealed the most striking pro-inflammatory RNA
signature with 15 markers upregulated after 24 h of CNP
inhalation suggesting endo/epithelial activation and in-
flammatory leucocyte accumulation. Again, only 3 genes
were upregulated after IAI exposure. A similar pattern
was observed for the protein profile, with several pro-
inflammatory proteins induced after CNP inhalation in
heart (24 h) and liver (4 h) samples (SPP1, IL-1b, IL-2, IL-
13, RETN and TGF-b1), but none after infusion (Fig. 6).
Due to limitations in sample weights, aortas were only
assessed for mRNA but not protein.
Discussion
Realizing the broad spectrum of the experiments per-
formed in this work and the corresponding data generated
following analysis of pulmonary and extra-pulmonary
body compartments, we have explained several aspects of
the findings along with the results. Summarizing the
events, our findings indicate that equivalent doses of
translocated CNP following inhalation - when intra-
arterially infused - do not cause appreciable extra-
pulmonary effects. Correspondingly, CNP inhalation in-
duces a very mild inflammatory response in lung tissue
with profound systemic effects. Among the studied target
organs, the aorta appears to exhibit a high susceptibility to
CNP. Increased transcript levels of neutrophil-related che-
moattractants (Cxcl2, −5; Lcn2) and macrophage markers
(Ncf1, −2; Saa3, Emr1) indicate plausible accumulation of
leukocytes in the aorta. Further, elevated levels of fibrino-
gens (Fga, −b, −g) suggests triggered homeostatic response
and blood leukocyte adhesion. Increased transcript levels
of markers associated with atherosclerosis or cardiovascu-
lar impairments (Edn1, Selp, Alox5, and Icam1) further in-
dicate plausible detrimental effects of CNP exposure on
aortic tissue at 24 h post inhalation. Increased levels of
Alox5, Emr1, Cxcl2, Saa3, Ncf1 and Ncf2 may also suggest
inflammatory phagocyte accumulation in the aorta for
24 h particle inhalation. These findings are supported by
the acute protein response in the liver, after 4 h inhalation
and in hematologic parameters, particularly platelet
Fig. 5 Expression profiling of acute phase reactants and systemic inflammation markers in the plasma of carbon nanoparticle (CNP) exposed
mice compared to control following inhalation and intra-arterial infusion. a. CNP exposure related changes of protein concentrations are shown as
percentage relative to control following 4 h and 24 h post inhalation is shown. b. CNP exposure related changes of protein concentrations are shown
as percentage relative to control following 4 h post intra-arterial infusion. Data are presented as Mean ± SEM; inhalation: n = 8, infusion: n = 6; and
asterisks (*) denote p < 0.05
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Fig. 6 Heatmap representation of the transcript (59 genes) and protein (34 analytes) panel profiling from heart, aorta and liver following carbon
nanoparticle (CNP) inhalation (4 h and 24 h) and intra-arterial infusion (4 h) comparing exposed versus control mice. a. Transcript expression levels
of 59 genes representing epithelial/endothelial activation, inflammatory cell markers, inflammation mediators and oxidative stress of heart, aorta
and liver are shown. b. Protein expression levels of 34 markers representing epithelial/endothelial activation, inflammatory cell markers, inflammation
mediators of heart and liver are shown. Samples were pooled from 4 animals/experimental group for transcript and protein analysis. Expression values
are provided as percentage relative to time matched control. Fold changes below 1.5 were considered insignificant and are indicated in black color.
Ox. stress: Oxidative Stress
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numbers as well as a decline in circulating activated leuco-
cytes. In spite of the fact that the observed pattern in this
study matches well with the previously described platelet
accumulation and fibrinogen deposition in the extra-
pulmonary microvasculature after CNP inhalation [35],
these findings are at this point only indicative of athero-
sclerotic susceptibility and warrant detailed mechanistic
investigations to substantiate a link to disease onset or
progression. Recently, Miller and colleagues [56] demon-
strated the accumulation of inhaled gold nanoparticles
(<10 nm) at the sites of vascular inflammation following
translocation in a size dependent manner. This find-
ing provides new evidence of a plausible contribution
of translocated nanoparticles in the pathogenesis of
atherosclerosis and cardiovascular diseases. In our IAI
study however, where an inflammatory response in
the lungs was bypassed and the retention of activated
blood leukocytes was absent, much less thrombocyto-
sis was observed, and the extra pulmonary organs of
investigation failed to show a pro-inflammatory signa-
ture. To match that to the accumulation data from
Miller and colleagues [56], it might be considered
that we used young and healthy mice, with now vas-
cular lesions, and that particles, smaller than 10 nm
may have more profound effects on extra-pulmonary
organs. Nevertheless our study indicates the aortic tis-
sue to be a susceptible organ for extra-pulmonary
particle effects.
Taken together, our data shows that CNP inhalation in-
duced a very mild inflammatory response in the lung but
provoked clear hematological alterations (increased num-
bers of circulating neutrophils and platelets, concomitant
with a decline in circulating activated leucocytes) and
clearly demarcating transcript expression changes in aorta
pointing to an inflammatory systemic irritation after 24 h
inhalation. In comparison, although many endpoints were
addressed, intra-arterial infusion of CNP induced only a
very modest systemic response. Thus, we conclude that
indirect (local particle-cell interactions in the lung) rather
than direct effects due to translocated CNP are mainly
governing the observed systemic effects. Taking into ac-
count the results from our previous study on platelet ac-
cumulation in the hepatic microvasculature [36] using
identical inhalation exposure settings (440 μg/m3, mass
median diameter 72 nm), we suggest that the extra-
pulmonary pro-thrombogenic effects represent the most
sensitive response to CNP inhalation. These pro-
thrombogenic effects may occur even in absence of any
detectable pulmonary or systemic inflammation as previ-
ously reported [31, 35]. The lack of any signs for extra-
pulmonary inflammation reported by the Khandoga et al.,
[35] study might be related to the use of C57BL/6 mice,
which are less prone to inflammatory reactions than the
BALB/c mice used here.
Limitations of the study
For technical reasons two different types of CNP had to
be used for inhalation (spark-discharge lab-generated
CNP) and IAI (Printex90) exposure. While this may be
considered as a weakness of the current study, there is
compelling evidence that both CNP types are very simi-
lar in terms of organic carbon content, oxidative potency
measured as ascorbic acid consumption (cell free) and
induction of lipoperoxidation in macrophages, when
expressed on a surface area basis [45]. Moreover, using
BET surface area is used as dose metric both CNP types
have been shown to display virtually identical pro-
inflammatory potencies (summarized in Additional file 1:
Table S8) suggesting similar underlying pathways of tox-
icity [28]. Intratracheal delivery of both CNPs types into
mice, equally affected peripheral blood cell numbers and
similarly as shown in Fig. 3. This compliant pattern for
spark-discharge and Printex 90 material, further supports
the comparability of the two CNPs. Nevertheless, the extra
pulmonary effects of inhaled Printex90 or intra-arterially
infused Palas particles remain hidden, and the use of dif-
ferent CNP materials remains a weak spot of the study
which cannot be overlooked. To consider the resulting
uncertainties we have aimed for a conservative dose ad-
justment and applied a maximal reasonable translocated
fraction of inhaled CNP by IAI, so as not to underestimate
the potential direct effects. Therefore, we argue that
adjusting the IAI-delivered systemic CNP surface area
dose to the upper limit of systemically available (translo-
cated) CNPs after inhalation (30 mm2) allows a compari-
son of direct and indirect CNP effects at equivalent doses
[41, 57]. Considering that on the one hand IAI-induced ef-
fects are smaller than those induced by inhaled CNPs,
while on the other hand the CNP dose delivered via IAI is
larger for a given period of time than the systemically
available CNP dose after inhalation, we argue that the lack
of response after IAI application cannot be seen as a result
of low IAI dosing. Instead, we consider the lack of re-
sponse after IAI suggests that particle-cell interactions in
the lung (indirect effect), to represent the key event of the
observed extra-pulmonary pro-thrombogenic effects fol-
lowing CNP inhalation. Another limiting factor could be
that interactions of the Krebs-Henseleit buffer (IAI ve-
hicle) with the suspended Printex90 particles may have al-
tered the surface properties of the IAI delivered CNPs as
compared to the inhaled-translocated CNPs. In 2% serum
dispersed Printex90 CNPs, however can even enhance
acute pulmonary inflammation upon instillation in com-
parison to pure water dispersions (unpublished observa-
tion). Nevertheless, the very same IAI application of these
Printex CNPs was able to cause systemic effects in the
hepatic microvasculature [34], arguing against persistent
passivation of Printex90 particle by incubation in Krebs-
Henseleit buffer. It is also possible that the higher stability
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of Printex90 in aqueous media to be due to hydrophilic
surface properties (e,g, high abundance of oxygenated
functionalities) which could likely be absent in the spark
discharge generated CNPs that appear to be more hydro-
phobic. Moreover, a purity of 95–98% may correspond to
significant differences of 2–5% impurity, is located par-
ticularly on the surface of particles. These differences in
particle characteristics between Printex 90 and spark dis-
charge generated may be considered as possible con-
founding factors.
Another potential drawback of the present study may
be the influence of the surgical procedure required for
IAI of CNPs which may have potential influence on the
expression of protein markers and transcripts. Also, we
focused the IAI- induced analysis on the 4 h time win-
dow because our previous studies indicated a 2 h inter-
val to be sufficient for platelet accumulation in the
hepatic microvasculature [34]. Pooling of samples for
transcript and protein analysis may also induce false
positives and negatives due to high inter sample vari-
ation in one group, such as extreme high or low values
in one or two samples. To further reduce the impact of
individual variations, we focused our analysis on changes
observed for marker patterns, in order to achieve a more
integral view. Additionally, though our present findings
following 4 h IAI exhibited no substantial response, and
also previous IAI results [34] do not demand for investi-
gations at later time points, yet we consider that using
additional animals to obtain IAI data at 24 h might have
been ideal to exclude that later response have not been
overlooked.
In spite of the limitations listed above, we are not
aware of any other study that allows for similar types of
conclusions and a direct comparison of dose-equivalent
systemic effects after inhalation-translocation and IAI of
CNPs. The methodological strength of the present study
is that the intra-arterially infused CNP dose was chosen
to match the estimated dose translocated from the lung
epithelium into the circulation after inhalation, so that
in the former case the particles circumvent pulmonary
accumulation and possible release of inflammatory me-
diators from the parenchyma of the lung. Finally, it is
noteworthy that our results are consistent with the hu-
man inhalation exposure study using identical spark-
discharge generated CNP, which reported alterations of
peripheral blood leukocyte distribution and expression
of adhesion molecules consistent with increased
leukocyte retention in the vascular bed [36]. However, in
a real-life exposure scenario, ambient particulate matter
will represent exposure a mixture of particles, gases,
volatile organic compounds etc. This can only be mim-
icked by using collected ambient dust. Thus, the expos-
ure scenario used in the current experimental set up is
restricted to the toxicology of insoluble CNPs.
Conclusion
This study shows that intra-arterial infusion of CNPs in-
duced only mild early effects in secondary (non-pulmon-
ary) target organs whereas inhalation of CNPs resulted
in both pulmonary and extra-pulmonary (particularly in
the aorta) responses. This indicates that the extra-
pulmonary effects after CNP inhalation require local,
pulmonary particle-cell interactions (indirect effect) and
that the translocated CNPs (direct effect) appear to be of
minor importance for the effects detected in extra-
pulmonary targets. Interestingly, the molecular signature
of the aorta proved to be most affected among the inves-
tigated extra-pulmonary tissues, displaying strong pro-
inflammatory reactions coupled with increased levels of
markers of atherosclerosis and endothelial dysfunction.
However, these findings are only indicative of potential
susceptibility that warrants detailed pathomechanistic
investigations as vascular dysfunction has not been in-
vestigated here. Our data demonstrates that inhalation-
mediated specific particle-lung cell interactions following
CNP exposure might alter the systemic homeostasis
leading to the retention of activated blood leucocytes in
the pulmonary vascular bed and might induce a set of
extra-pulmonary molecular reactions. Finally, the signifi-
cant effect observed in the aortic tissue suggests the
aorta to be an important extra-pulmonary target of
CNP-mediated effects following the pulmonary response
to inhaled CNPs that warrants more detailed investiga-
tions in future studies.
Methods
Animals
Female BALB/cJ mice (10–12 weeks) housed under spe-
cific pathogen free conditions at the animal facility of
the Helmholtz Zentrum München were used for the ex-
periments. The inhalation and IAI groups consisted of
n = 16 and n = 6 animals, respectively, for each of the
experimental groups per time point. All experimental
procedures were approved by the Bavarian Animal Re-
search Authority (Approval no: 55.2–1–54-2531-115-05)
in accordance with German law of animal protection.
Animal numbers, experimental groups and overall ex-
perimental design are described in Additional file 1:
Table S8 and Fig. 7.
Particle types used for inhalation and intra-arterial
infusion (IAI)
Ideally, identical CNPs should be used for inhalation and
IAI exposure. For delivery of the highest possible lung-
deposited CNP (surface area) dose rate in the ultrafine
size range (<100 nm) via inhalation laboratory-generated
spark-discharge CNP aerosol is the most suitable particle
type [58]. Unfortunately, this particle type revealed to be
not sufficiently stable in the Krebs-Henseleit buffer, the
Ganguly et al. Particle and Fibre Toxicology  (2017) 14:19 Page 12 of 17
vehicle used for IAI application, and thus the previously
used [34] commercially available carbon nanoparticles
(Printex 90, Degussa, Frankfurt, Germany) were used
for IAI exposure. These two types of particles have
very similar physicochemical properties (spark dis-
charge/Printex 90 CNPs), namely chemical compos-
ition (≥98%/≥95% elemental carbon, no bioavailable
organic compounds), agglomerated spherical primary
carbon particles with primary particle diameter of
10 ± 2 nm/14 ± 2 nm; Brunauer–Emmett–Teller
(BET) surface area of 800 m2/g / 300 m2/g [24, 44,
45, 59]. Importantly, for both types of highly pure
carbon particles the acute pulmonary toxicity in mice
scales extremely well with BET surface area [44] and
is directly related to the pro-oxidative surface activity,
i.e., the surface specific toxicity is identical among the
two types of CNPs [28]. These particle characteristics
are summarized in the Additional file 1: Table S9.
The preference of surface area as most predictive
dose metric (rather than mass or number) for acute
pulmonary effects, has not only been shown for a
wide variety of carbonaceous but also for metal oxide
and polymeric materials [60, 61]. Thus, BET surface
area was used as dose metric to determine an equiva-
lent dose of infused CNPs (Printex 90; mass-specific
BET surface area: 300 m2/g) corresponding to the
translocated dose of CNPs (spark discharge; 800 m2/g)
after inhalation exposure [28, 44].
Fig. 7 Schematic representation of the experimental strategy. The figure outlines the rationale and corresponding experimental strategy to
compare and contrast the pulmonary and extra-pulmonary effects of carbon nanoparticle (CNP) exposure following inhalation and intra-
arterial infusion in BALB/cJ mice. BAL: bronchoalveolar lavage; BET: Brunauer–Emmett–Teller; CNP: carbon nanoparticle; FACS: fluorescence
automated cell sorting
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Inhalation of CNPs: The set-up of the whole-body ex-
posure system for rodents used in this study has been
previously described [30, 62]. Mice (n = 16) were simul-
taneously exposed for 4 or 24 h to either filtered air or
spark discharge generated CNPs at a mass concentration
of 440 μg/m3 corresponding to a BET surface area con-
centration of 3.5 × 105 mm2/m3 with a number- and
mass-based median diameter of 48 and 72 nm, respect-
ively, and a geometric standard deviation (width) of the
size distribution of 1.55. For these conditions, more than
80% of the CNP mass is in the ultrafine size range
(below 100 nm). Please refer to Additional file 1 for
more details.
Translocated surface area dose after CNP inhalation
For assessment of the role of direct systemic particle ef-
fects after inhalation exposure, CNPs were intra-
arterially infused (IAI) directly into the blood stream.
The infused CNP surface area dose was chosen to match
the CNP dose likely to be translocated from the lung to
the blood stream during a 24 h inhalation exposure. As
a worst case scenario the maximal translocated particle
dose was estimated from the inhaled CNP surface area
concentration (3.5 × 105 mm2/m3) and literature values
for the inhaled air volume during 24 inhalation (66 ml/
min × 24 h = 0.095 m3) [63]; the lung deposited aerosol
fraction of 34% for nanoparticles with a similar size distri-
bution as used here [64] and the translocated fraction of
the lung deposited dose of 0.3%, which implies that the
lung deposited surface area dose is 330-fold higher
(10,000 mm2) than the translocated dose. This number is
derived from 0.1% translocation according to Kreyling et
al., [23] and a safety factor of 3 accounting for uncertainties
due to differences in particle type and animal model). As
all of the relevant parameters were estimated conserva-
tively (towards the highest possible dose, the resulting
translocated dose of 30 mm2 for 24 h CNP inhalation can
be considered an upper limit of the translocated CNP dose
[Additional file 1, extended materials and methods].
IAI of CNP
For IAI, commercially available CNPs (Printex 90,
Degussa, Frankfurt, Germany), suspended in 200 μl
Krebs-Henseleit buffer, were infused in mice (n = 6)
through a catheter introduced into the aortic arch via
the carotid artery and analyzed after 4 h. Mice intra-
arterially infused with only Krebs-Henseleit buffer
(i.e., vehicle) served as the corresponding control [34],
[Additional file 1, extended materials and methods].
Similar to the inhalation route, more than 50% of the
applied (agglomerated) CNPs mass was in the ultrafine
size range (UfCP, mass-weighted (mobility) diameter
below 100 nm). This was accomplished by carefully pro-
cessing the initial CNPs suspension according to a
sequence of filtration and vortexing steps [65]. For
comparison of the biological response of inhaled-
translocated and intra-arterially infused CNPs both
doses were matched. Using the dosimetry method for
CNPs described by Stampfl et al. [65] 30 mm2 of
CNPs, which corresponds to 110 ng of CNPs
(300 m2/g for Printex 90), were infused representing
the maximum dose of inhaled-translocated CNPs as
described above. Thus, the observed biological effects
after intra-arterial infusion represents an upper limit
of the expected direct effect of particle translocation
from the lung to the blood stream after 24 h CNP in-
halation (and even more so after 4 h inhalation).
Animal procedures and molecular analysis
Mice were anesthetized by intraperitoneal injection of
xylazine (4.1 μg/g) and ketamine (188.3 μg/g), blood was
withdrawn from the retro-orbital plexus and collected in
EDTA tubes (Sarstedt, Hannover, Germany) followed by
exsanguination and bronchoalveolar lavage (BAL) as
previously described [44]. Analysis of BAL cell differen-
tials, BAL total protein content, hematology, and lung
histology was performed. To abide by the “3R” (replace,
reduce and refine) principles of animal protection, in-
flammatory response in the lungs of IAI exposed mice
was assessed based on the most sensitive method in a
minimal number of mice, namely expression analysis
only (no BAL analysis), since only very low pulmonary
effects were expected. Transcript and/or protein expres-
sion analysis for both control and experimental groups
(4 h and 24 h inhalation, 4 h intra-arterial infusion) were
performed using BAL fluid, plasma, lung, heart, liver,
and aorta using panel assays as described in the supple-
mentary section. Blood samples were also analyzed for
monocyte and granulocyte activation using flow cytome-
try (LSR II, Becton Dickinson) and FlowJo Software
(Version:7.2.2, Tree Star, Oregon). Granulocytes were
defined as [GR1+Ly6G+] and monocytes as [GR1+Ly6G−]
cells. Additionally, we also investigated three integrin
cell surface markers, namely integrin alpha M (CD11b),
alpha-4 integrin (CD49d) and beta-2 integrin (CD18)
due to their established role in leukocyte-endothelial
interaction and their association with human particle in-
halation [36]. For transcript and protein expression ana-
lysis, samples were pooled from 4–6 animals for each
experimental group.
Statistical analysis
Statistical analysis was performed by student’s t-test
comparing time-matched control and CNP exposed
groups. Statistical significance was set at p < 0.05. Values
are given as mean ± standard error of the mean (SEM).
CNP exposure-related effects are typically expressed as
changes relative to the time matched control.
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Additional file
Additional file 1: Table S1. Summary of the main findings following
carbon nanoparticle (CNP) inhalation and intra-arterial infusion in BALB/cJ
mice. ↑: Increased ↓: Decreased. Table S2: BAL cell differentials are shown
in counts 4 and 24 h after clean air (Contol) or carbon nanoparticle (CNP)
inhalation. Values measured out of range were defined as: <OOR. Macro:
macrophages, Lympho: lymphocytes, Neutro: neutrophil granulocyte,
EOS: eosinophil. Means ± SEM, Inhalation: n = 8; infusion: n = 6; *
p ≤ 0.05. Table S3: BAL cytokine concentrations: Protein markers in BAL
samples of mice 4 h and 24 h after clean air (Control) or carbon nanoparticle
(CNP) inhalation. Values measured out of range were defined as: <OOR.
CCL2: Monocyte chemoattractant protein-1 (MCP-1), CXCL1: Growth-
regulated alpha protein (KC), G-CSF: Granulocyte colony stimulating factor,
GM-CSF: Granulocyte-macrophage colony stimulating factor 2, IFN-gamma:
Interferon gamma, IL: Interleukin, TNF-alpha: Tumor necrosis factor alpha.
Mean ± SEM, * p ≤ 0.05. n = 8. Table S4: Gene annotation and primer
sequences of the transcripts analyzed: List of the 59 transcripts analyzed
by quantitative RT-PCR with respective primer pairs. Expression of Hprt1
expression served as control. Table S5: Haematological analysis Haematological
analysis of blood samples 4 and 24 h after clean air (Control) or carbon
nanoparticle (CNP) inhalation and 4 h after sham (Control) or CNP infusion.
RBC: red blood cells, WBC: white blood cells, Lympho: lymphocytes, Neutro:
neutrophil granulocyte, EOS: eosinophil granulocyte, Baso: basophil granulocyte,
Mono: monocytes, PLT: platelets, Large PLT: large platelets. Means ± SEM, *
p < 0.05. Inhalation: n = 8/group; Infusion: n = 6/group. Table S6: Multiplex
protein suspension array Protein markers in plasma samples of mice 4 and
24 h after clean air (Control) or carbon nanoparticle (CNP) inhalation and 4 h
after sham (Control) or CNP infusion. Values measured out of range were
defined as: <OOR. CCL2: Monocyte chemoattractant protein-1 (MCP-1), CCL5:
RANTES, CXCL1: Growth-regulated alpha protein (KC), E-selectin: Endothelial
leukocyte adhesion molecule 1, G-CSF: Granulocyte colony stimulating factor,
GM-CSF: Granulocyte-macrophage colony stimulating factor 2, IFN-gamma:
Interferon gamma, IL: Interleukin, MMP9: Matrix metalloproteinase-9, sICAM-1:
soluble Intercellular adhesion molecule 1, sVCAM-1: soluble Vascular adhesion
molecule 1, TNF-alpha: Tumor necrosis factor alpha, total PAI-1: total
Plasminogen activator inhibitor 1. Inhalation: n = 8; infusion: n = 6;
Mean ± SEM, * p < 0,05. Table S7: Multiplex protein expression
Protein expression analysis (pg/ml) of lung, heart and liver tissue 4
and 24 h after clean air (Control) or carbon nanoparticle (CNP)
inhalation and 4 h after sham (Control) or CNP infusion. CCL2:
Monocyte chemoattractant protein-1 (MCP-1), CCL3: MIP-1-alpha,
CCL4: MIP-1-beta, CRP: C-reactive protein. CXCL1: Growth-regulated
alpha protein (KC), CXCL2: Macrophage inflammatory protein 2
(MIP2), CXCL12: Stromal cell-derived factor 1 (SDF-1), E-selectin:
Endothelial leukocyte adhesion molecule 1, GM-CSF: Granulocyte-
macrophage colony stimulating factor 2, ICAM-1: Intercellular adhesion
molecule 1, IFN-gamma: Interferon gamma, IL: Interleukin, L-selectin: Leukocyte
adhesion molecule 1 (CD62L antigen), MMP2: Matrix metalloproteinase-2,
MMP9: Matrix metalloproteinase-9, PDGF-AA: Platelet-derived growth factor A
chain (dimer), PDGF-BB: Platelet-derived growth factor B chains (dimer), P-
selectin: Leukocyte-endothelial cell adhesion molecule 3 (CD62P antigen), TGF-
beta-1: Transforming growth factor beta-1, TNF-alpha: Tumor necrosis factor
alpha, TNF-RI: Tumor necrosis factor receptor superfamily member 1A, VCAM-
1: Vascular adhesion molecule 1, VEGF: Vascular endothelial growth factor.
Samples were pooled from 4 animals/experimental group for gene and
protein analysis. Table S8: Animal distribution for each experiment. CNP:
Carbon nanoparticle; FACS: Fluorescence automated cell sorter. Table S9:
Comparison of the properties form Printex 90 (IAI) and Palas spark-discharge
(Inhalation) carbon nanoparticles (CNP). (DOCX 106 kb)
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